Single-use bioprocessing systems have transformed pharmaceutical manufacturing economics, eliminating cleaning validation, reducing cross-contamination risk, and dramatically lowering the capital cost of biopharmaceutical production. They have also created one of the most difficult plastic waste management challenges in the life sciences industry. Every production run generates kilograms of plastic — bags, tubing sets, filters, connectors, and accessories — that has been in contact with biological material and must be biologically inactivated before it leaves the containment space. That inactivation requirement eliminates the standard recycling pathways that work for other laboratory plastics and makes bioprocessing single-use waste one of the least addressed waste streams in pharmaceutical sustainability programs.

This article addresses single-use plastic waste reduction strategies specific to GMP bioprocessing production environments. For the complete operational context, see Lab Manager's Bioprocessing Lab Operations: The Complete Lab Manager's Guide. For general laboratory plastic sustainability strategies applicable to non-GMP lab settings, Lab Manager's guide to integrating sustainability across lab design, procurement, and operations and the practical approaches to rethinking waste in the lab provide relevant background.

Why General Lab Plastic Sustainability Strategies Often Do Not Apply to Bioprocessing

The general lab sustainability playbook — reduce, reuse, recycle, then compost or responsibly dispose — does not transfer directly to GMP bioprocessing single-use waste because of one defining constraint: the decontamination requirement. Single-use components that have been in contact with biological material or pharmaceutical product must be biologically inactivated before they exit the containment space. Autoclave inactivation (the standard approach) subjects the plastic to conditions that degrade many polymers, reducing their value for mechanical recycling. It also adds contamination status complexity that most municipal or commercial recycling programs are not equipped to handle.

This does not mean recycling is impossible. It means that the recycling pathway for bioprocessing single-use waste requires different infrastructure than general lab plastics, typically through specialized programs that handle decontaminated pharmaceutical waste and have validated processes for converting it into recycled material. Understanding this constraint is the starting point for any realistic bioprocessing sustainability program.

For the broader context of single-use bioprocessing technology and its adoption trajectory, see Lab Manager's analysis of the operational and automation trends driving single-use bioprocessing adoption. The BioPhorum industry consortium has published specific guidance on single-use sustainability in biopharmaceutical manufacturing, including waste classification frameworks and supplier engagement protocols.

Lab Quality Management Certificate

The Lab Quality Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

Starting With a Waste Audit

Most bioprocessing facilities do not have accurate data on how much single-use plastic they generate, by component category, per batch. Without that baseline, sustainability reduction targets are arbitrary, and progress cannot be measured. A waste audit specific to bioprocessing single-use components is the essential first step.

The audit should quantify waste by component category (process bags, tubing assemblies, filters, sterile connectors, accessories, and packaging materials), by contamination status (product-contact vs. non-product-contact), and by batch or production campaign. The resulting data reveals the high-volume, high-weight components that should be the primary focus of reduction efforts and identifies the non-product-contact waste streams that are most amenable to standard recycling without the full decontamination burden.

GMP-Compliant Decontamination: The Gateway to Recycling

Before any bioprocessing single-use component can enter a recycling program, it must be biologically inactivated under a validated procedure. Autoclave inactivation is the most commonly used method: the waste is loaded into autoclave bags, processed at a cycle validated to achieve the required biological kill for the specific agents used in the facility, and then transferred to the solid waste stream as biologically inactive material. The validation of the autoclave inactivation cycle, including the load configuration, temperature profile, and achieved kill, must be documented and treated as a GMP record.

Interested in lab design?

Register for a FREE Lab Manager account to subscribe to the Lab Design Newsletter from our sister site, Lab Design News.

Subscribe for Free

Chemical inactivation (adding a validated disinfectant concentration to the liquid contents before draining) is used for large-volume bag contents where autoclaving the filled bag is impractical. The chemical agent, concentration, contact time, and pH must be validated for each agent combination, and the inactivated liquid disposed of through the appropriate chemical waste pathway. Both approaches generate GMP documentation that provides the evidence basis for any subsequent claims that the material has been biologically inactivated.

Vendor Take-Back and Recycling Programs

Major bioprocessing equipment suppliers have established take-back programs that accept decontaminated single-use waste and process it into recycled materials, typically through specialized industrial recycling pathways that handle pharmaceutical-grade polymer waste. These programs represent the most practical near-term recycling option for product-contact single-use components in GMP bioprocessing facilities.

Program specifics vary significantly between suppliers, and facilities evaluating take-back programs should request specific information on: which components are accepted (not all components from a given supplier may be eligible), what documentation of inactivation is required (certificate of decontamination, autoclave records, or vendor-specific declaration), what the recycled material is converted to (recycled polymer for non-medical applications, energy recovery, or chemical recycling), and what the carbon accounting and ESG reporting value of participation is for the facility's sustainability metrics.

The practical limitation of vendor take-back programs is scale and logistics: waste must be segregated, inactivated, documented, and shipped back to the supplier or their designated recycling partner. For facilities with high single-use volumes, this can represent a meaningful operational effort, but the waste diversion metrics and ESG reporting value may justify the investment at scale.

For the broader context of lab plastic recycling innovations and circular economy approaches applicable across scientific settings, Lab Manager's recycling lab plastics: success stories and closing the loop through circular economy practices in labs provide useful context on what is working elsewhere. The EPA's resources on sustainable plastics management provide the US regulatory and statistical context for industrial plastic waste.

Reduction at the Source: Cutting Waste Before It Is Generated

The most effective waste reduction strategy for any material is generating less of it. In bioprocessing, source reduction opportunities exist in procurement optimization, campaign planning, and in some cases, component design.

• Buffer and media preparation consolidation: combining multiple small bag preparations into fewer large bags per production campaign reduces the total number of assemblies generated and the total plastic weight per batch
• Size optimization: right-sizing bag volumes to actual working volumes eliminates the overhang in standard catalog sizes and reduces material used per unit of product
• Non-contact component reuse: specific non-product-contact components such as stainless steel tubing clamps and reusable plastic housings can be reused across campaigns with appropriate cleaning procedures, where GMP documentation supports the practice
• Packaging reduction through supplier collaboration: requesting reduced packaging from single-use component suppliers (fewer inner packaging layers, recyclable outer cartons) is a low-cost intervention with measurable impact on total facility plastic footprint
• Campaign efficiency: producing more product per batch — through process optimization that improves titer or yield — generates the same output with proportionally less single-use material

Emerging Materials and the Future of Bioprocessing Sustainability

The bioprocessing industry is actively developing single-use components manufactured from more sustainable materials: mechanically recyclable polymers, bio-based feedstocks, and multilayer films designed to be separated and recycled rather than disposed of as mixed material. These materials are emerging from the development phase and beginning to enter commercial availability, but they face a material challenge specific to the regulated environment: any change in the material composition of a single-use component in contact with a pharmaceutical product may constitute a regulatory change requiring post-approval submission or, at minimum, a formal change control assessment.

Regulatory acceptance of sustainable single-use materials is developing in parallel with the materials themselves. Facilities watching this space should engage their major suppliers directly on their sustainable materials roadmaps, participate in industry working groups (including BioPhorum workstreams focused on single-use sustainability), and begin building the internal regulatory affairs capability to manage single-use material changes as they become available. The facilities that have invested in understanding the regulatory pathway for material changes will be first to convert when sustainable alternatives achieve acceptable performance and regulatory clearance.

ESG Reporting on Single-Use Waste

Investor and customer ESG requirements for biopharma companies increasingly include plastic waste reporting, and single-use bioprocessing waste is a significant and growing component of those disclosures. Facilities that do not have measurement systems for single-use waste generation, diversion, and disposal will find it difficult to produce credible ESG reports when reporting requirements reach them, whether from institutional investors, major biopharma customers, or regulatory disclosure requirements.

Building a measurement system now, even before it is required, positions a facility to demonstrate meaningful progress over time. The key metrics to track are: total single-use plastic generated per year (kg) and per batch (kg/batch); waste diverted from landfill through vendor take-back, recycling, or energy recovery programs; and the carbon footprint of single-use plastic inactivation (autoclave energy consumption is itself a sustainability consideration). Lab Manager's practical guide to improving sustainability in the lab covers the measurement frameworks applicable across laboratory sustainability programs.

This article was produced under Lab Manager's AI Editorial Guidelines